3 years after the FDA forced Chiasma back into PhIII, they’re back with positive data — but now they have a rival
Three long years after Chiasma $CHMA was barred at the front gate of the FDA and forced back to the clinic to do a new, controlled Phase III study of its acromegaly drug octreotide, they’ve got a p-value to take to regulators.
And this time it may stick — though the competitive scene has changed since Chiasma’s regulatory woes hit. Their data — while positive — are a little worse this time, which rival Crinetics $CRNX will now try to use against them.
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
